Showing posts with label Trastuzumab. Show all posts
Showing posts with label Trastuzumab. Show all posts
Friday, March 09, 2012
Activity and resistance of trastuzumab according to different clinical settings
Activity and resistance of trastuzumab according to different clinical settings: Publication year: 2012
Trastuzumab, a humanized monoclonal antibody directed against HER2, has shown efficacy in breast cancers; however many patients do not respond to this reagent. Here, we discuss the potential mechanisms of trastuzumab efficacy and resistance in different clinical settings as a step toward optimizing the appropriate application of this antibody. The three major antitumor mechanisms of trastuzumab, i.e., inhibition of proliferation, antibody-dependent cell cytotoxicity (ADCC) and inhibition of DNA repair, appear to be differentially operative in different clinical settings. ADCC appears to be the prevalent mechanism in trastuzumab neoadjuvant monotherapy, whereas in neoadjuvant, adjuvant or metastatic settings in which trastuzumab is combined with chemotherapy, the relative role of ADCC is probably small, considering the compromising effects of chemotherapy on the immune cells that mediate this mechanism. In neoadjuvant and adjuvant settings involving concomitant use of trastuzumab and chemotherapy, the primary mechanism at play is presumably inhibition of DNA repair by the antibody, while in sequential protocols, the antibody acts mostly by exerting cytostatic activity through inhibition of HER2-mediated tumor cell proliferation. According to the ability of the antibody to induce cytotoxic or cytostatic antitumor effects depending on the clinical setting, different criteria, i.e., RECIST for cytotoxic effect, OS, and DFS for cytostatic, must be considered in accurately estimating antibody efficacy. Moreover, since trastuzumab resistance likely depends directly on the mechanisms responsible for its antitumor activity, resistance mechanisms must also be considered with respect to the different clinical settings.
add your opinions
HER2
,
monoclonal antibody
,
Trastuzumab
Saturday, May 21, 2011
Tuesday, May 03, 2011
NCI Cancer Bulletin: (U.S.) FDA Approves Test to Identify Candidates for Breast Cancer Drug - Trastuzumab (Herceptin) - HER2 gene
FDA Approves Test to Identify Candidates for Breast Cancer Drug
The Food and Drug Administration (FDA) has approved a genetic test that doctors can use to help identify women with breast cancer who have extra copies of the HER2 gene and therefore may benefit from the drug trastuzumab (Herceptin).Trastuzumab targets the protein made by the HER2 gene, which is located on chromosome 17. Approximately 25 percent of breast cancers have extra copies of the HER2 gene and produce higher levels of the HER2 protein. These tumors tend to grow faster and are more likely to recur than tumors that don’t overexpress HER2........cont'd
add your opinions
FDA
,
HER2 gene
,
Herceptin
,
Trastuzumab
Sunday, April 17, 2011
Trastuzumab (Herceptin) Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities -- The Oncologist
Note: Trastuzumab is also known as Herceptin "Based on these considerations, it would be interesting if Extra and colleagues could reanalyze their data by distinguishing patients stopping trastuzumab according to whether or not they had "equal opportunities" to patients continuing trastuzumab beyond progression." (The Oncologist) Editor's note: Dr. Extra was invited to reply but declined comment.
add your opinions
extracolonic
,
Herceptin
,
Trastuzumab
Tuesday, March 15, 2011
Friday, June 04, 2010
Abstract/full free access: The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
In research/technical:
Conclusions
Cetuximab (Erbitux) and trastuzumab (Herceptin) distribute slowly, but at higher doses achieve a relatively uniform distribution after about 24 hours, most likely due to their long half-lives in the circulation. There remains poor distribution within hypoxic (hypoxia - a deficiency of oxygen reaching the tissues of the body) regions of tumors.
add your opinions
Cetuximab
,
hypoxia
,
Trastuzumab
Subscribe to:
Posts
(
Atom
)